Radar · Life Sciences in Texas
Best Life Sciences Companies in Texas, United States
The 904 best Life Sciences companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Verily.
By Riya SenguptaFinancials
904companies tracked
$13Bdisclosed funding
3unicorns
398have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × TEXAS
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
383kcombined LinkedIn audience
62%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Verily 🦄 A data platform and technology company purpose-built to power AI-enabled precision health 84News top 13%Funding top 14%Talent top 22%Growth top 25% All 12 signals ▾Newstop 13% Fundingtop 14% Talenttop 22% Growthtop 25% Moattop 26% Techtop 30% Markettop 31% Producttop 32% Customerstop 34% Partnerstop 41% Innovationtop 42% Globaltop 48% News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 84/100 | $2.5B | 3 mo ago | 1,564 | Andrew Conrad Co-Founder | Apple iCloud MailGoogle WorkspaceNode.js+24 | — | — |
| 2 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | — | WordPress Site EditorCart FunctionalityWordPress+19 | — | — |
| 3 | Lexicon Pharmaceuticals Developer of small molecule drugs for diffrent health diseases 76Funding top 20%Patents top 24%Talent top 28%Growth top 30% All 11 signals ▾Fundingtop 20% Patentstop 24% Talenttop 28% Growthtop 30% Techtop 35% Innovationtop 40% Markettop 41% Fin. healthtop 41% Moattop 44% Newstop 45% Globalbottom 44% Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $381M | 4 mo ago | 135 135 → 284 (+110%) · sector median +24% | Ivan Cheung Board of Directors | DrupalApple iCloud MailPHP+31 | 1,211 patents Patents concentrated in chemistry & materials | — |
| 4 | EndoQuest Robotics Developer of a robotic system for endoluminal and single-incision surgery 53Innovation top 15%Patents top 22%Funding top 26%Moat top 41% All 9 signals ▾Innovationtop 15% Patentstop 22% Fundingtop 26% Moattop 41% Talentbottom 49% Techbottom 43% Newsbottom 42% Globalbottom 40% Marketbottom 31% Innovation: 135 patents (top 15% of patent-holders) · 131 filings since 2022 vs 4 in 2017-21 Patents: 135 patents matched (strict assignee match) · 131 filings since 2022 vs 4 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $202M | 12 mo ago | 21 | Kurt Azarbarzin CEO | ExpressionEnginePHPVimeo+18 | 135 patents Robotic surgical system control, instrumentation, and safety components for minimally invasive procedures | — |
| 5 | Shattuck Labs Developer of an immunotherapy platform for oncology and other diseases | $165M | 9 mo ago | 89 89 → 57 (-36%) · sector median +24% | — | WordPress Block EditorWordPressApple iCloud Mail+20 | 305 patents Bispecific immunomodulatory antibodies and TRIM7‑targeted protein therapeutics, including mRNA formats. | — |
| 6 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 9 mo ago | 67 | — | DrupalApple iCloud MailMicrosoft 365+22 | — | — |
| 7 | CoRegen Developer of a novel cancer therapy targeting Treg cells | $121M | 11 mo ago | — | John Thomas CFO | — | — | — |
| 8 | MicroTransponder Developer of neuromodulation therapy for neurological conditions | $115M | 15 mo ago | 33 | Jordan Curnes Co-Founder & President | WixSentryBootstrap+10 | 87 patents Vagus nerve stimulation integrated with motor and therapeutic rehabilitation devices | — |
| 9 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 9 mo ago | 85 85 → 60 (-29%) · sector median +24% | — | WordPressApple iCloud MailMySQL+25 | — | 2 partnerships |
| 10 | Alleviant Medical Developer of devices to lift the burden of heart failure | $89M | 15 mo ago | 37 | Jacob Kriegel Md Co-Founder & CMO | BugHerdNode.jsMonaco Editor+23 | — | — |
| 11 | Actuate Therapeutics Developer of therapeutics for hard-to-treat cancer | $72M | 11 mo ago | 6 | Dan Schmitt President and CEO | WordPressMySQLPHP+16 | — | 1 launch |
| 12 | OncoNano Developer of a compound that exploits pH as a biomarker to diagnose and treat cancer | $68M | 14 mo ago | 20 20 → 22 (+10%) · sector median +24% | Marty Driscoll CEO | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | — |
| 13 | Pattern Bioscience Provider of multiple diagnostics platforms for infectious diseases 60Patents top 20%Funding top 25%Innovation top 26%Moat top 32% All 10 signals ▾Patentstop 20% Fundingtop 25% Innovationtop 26% Moattop 32% Growthtop 37% Talenttop 38% Techbottom 46% Marketbottom 38% Globalbottom 38% Newsbottom 22% Patents: 58 patents matched (strict assignee match) · 42 filings since 2022 vs 16 in 2017-21 Funding: Raised $68.0M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $68M | 10 mo ago | 58 58 → 77 (+33%) · sector median +24% | Ross Johnson Co-Founder | WordPressMySQLPHP+20 | 58 patents Microfluidic single-cell analysis platforms for diagnostic and phenotypic screening | 1 award |
| 14 | Gradalis Personalized cancer immunotherapy company advancing treatment through Vigil platform | $68M | 12 mo ago | 8 | — | — | 179 patents Nucleic‑acid therapeutics targeting cancer and genetic muscle disorders, including RNAi and neoantigen vaccines. | — |
| 15 | Xequel Bio Developer of therapeutics for multiple indications | $63M | 16 mo ago | 16 | Jerry Peter CEO | — | — | — |
| 16 | VeraDermics Developer of drug-delivery solution for the treatment of pediatric wart treatment | $38M | 8 mo ago | 8 | Kyle Ryder Founder | DrupalPHPAmazon Web Services+21 | 76 patents Controlled-release topical minoxidil pharmaceutical formulations for hair growth | 3 job openings · 1 launch |
| 17 | March Biosciences Developer of CAR-T cell therapies for malignancies | $33M | 20 mo ago | — | Max Mamonkin Co-Founder and CSO | — | — | — |
| 18 | Nacuity Pharmaceuticals Developer of therapies for treating retinitis pigmentosa | $31M | 6 mo ago | 7 | Halden Conner CEO & President | WordPressMySQLPHP+16 | — | — |
| 19 | XCath Developer of endovascular robotics and steerable guidewires 45Innovation top 23%Patents top 26%Funding top 28%Moat top 28% All 7 signals ▾Innovationtop 23% Patentstop 26% Fundingtop 28% Moattop 28% Talentbottom 49% Globalbottom 40% Marketbottom 24% Innovation: 128 patents (top 15% of patent-holders) · 72 filings since 2022 vs 56 in 2017-21 Patents: 128 patents matched (strict assignee match) · 72 filings since 2022 vs 56 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 3 mo ago | 10 | Eduardo Fonseca CEO | — | 128 patents Patents concentrated in health & consumer products | — |
| 20 | CoRegen Developer of immunotherapeutics for the treatment of cancer | $27M | 13 mo ago | — | Steve Gorlin CEO | — | — | — |
| 21 | PLUS THERAPEUTICS Provider of therapeutics for multiple cancer treatments | $24M | 15 mo ago | 20 20 → 27 (+35%) · sector median +24% | Marc Hedrick CEO | WordPressBugHerdApple iCloud Mail+39 | — | 1 partnership |
| 22 | CNS Pharmaceuticals Developer of treatments for primary and metastatic cancers in the brain and central nervous system 42Funding top 23%News top 23%Growth top 25%Talent top 43% All 7 signals ▾Fundingtop 23% Newstop 23% Growthtop 25% Talenttop 43% Techbottom 45% Globalbottom 43% Marketbottom 19% Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $23M | 1 mo ago | 5 | John Climaco CEO | WordPressMySQLPHP+15 | — | 1 job opening |
| 23 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | Sudhish Sharma Co-Founder | WordPressMySQLPHP+14 | — | — |
| 24 | Nuclein Developer of handheld PCR device for the detection of infectious disease | $20M | 11 mo ago | 27 | Alan Blake Chief Executive Officer | WordPressMySQLPHP+25 | 24 patents Molecular diagnostic kits: nucleic acid extraction, amplification, and reagent stabilization. | 1 expansion |
| 25 | QbDVision Provider of a platform for process management software for pharma manufacturing 42Funding top 36%Talent top 38%Moat top 39%Growth top 45% All 8 signals ▾Fundingtop 36% Talenttop 38% Moattop 39% Growthtop 45% Techtop 49% Marketbottom 39% Globalbottom 29% Newsbottom 27% Funding: Raised $20.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $20M | 14 mo ago | 43 | Ryan Shillington Co-Founder and CTO | WordPressMySQLPHP+40 | — | 1 partnership · 1 award |
| 26 | NanoScope Technologies Instruments and devices for biomedical application 13Funding top 43%Market bottom 32%Global bottom 29% All 3 signals ▾Fundingtop 43% Marketbottom 32% Globalbottom 29% Funding: Raised $17.6M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) Market: 18 employees rank vs industry peers · Fliar Intelligence Index 13/100 | $18M | 8 mo ago | 18 | — | — | — | — |
| 27 | Bondwell Technologies Developer of protein-based biomaterial platform for energy, environment, and medicine | $17M | 15 mo ago | 10 | David Howell S President and CEO | — | — | — |
| 28 | Spark Biomedical Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment 53Patents top 23%Innovation top 26%Funding top 32%Moat top 38% All 10 signals ▾Patentstop 23% Innovationtop 26% Fundingtop 32% Moattop 38% Techtop 40% Growthtop 45% Talentbottom 49% Productbottom 48% Globalbottom 40% Marketbottom 29% Patents: 61 patents matched (strict assignee match) · 55 filings since 2022 vs 6 in 2017-21 Innovation: 61 patents (top 27% of patent-holders) · 55 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 9 mo ago | 18 18 → 27 (+50%) · sector median +24% | Daniel Powell CEO | WebflowMemberStackJava+29 | 61 patents Non‑invasive auricular neurostimulation devices for women's health therapies | 1 award |
| 29 | StemBioSys Cell culture technology company advancing regenerative medicine and drug discovery | $15M | 16 mo ago | 9 | Robert Hutchens President & CEO; Member of the Board of Directors | Cart FunctionalitySquarespace CommerceSquarespace+16 | 24 patents Amniotic fluid-derived ECM for cardiac tissue engineering and cardiotoxicity screening | 3 launchs |
| 30 | Asylia Therapeutics Developer of medicines for cancer, autoimmune, and infectious diseases | $14M | 14 mo ago | 4 | Richard Jones Co-Founder | — | — | — |
| 31 | 4WEB Medical Innovative orthopedic implant company focused on advanced structural design and fusion 40Funding top 39%Growth top 45%Tech top 46%Talent bottom 49% All 8 signals ▾Fundingtop 39% Growthtop 45% Techtop 46% Talentbottom 49% Productbottom 48% Marketbottom 41% Globalbottom 29% Newsbottom 22% Funding: Raised $12.5M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $12M | 14 mo ago | 49 | Jessee Hunt Founder & CEO | WordPressApple iCloud MailMySQL+25 | — | 1 internship · 5 launchs |
| 32 | Diakonos Provider of immunotherapeutics for cancer treatment | $11M | 12 mo ago | — | Mike Wicks CEO | WordPressMySQLPHP+18 | — | 1 partnership |
| 33 | MaxWell Biosciences Engineering personalized human blood to optimize cognitive performance and reverse Alzheimer's disease | $11M | 10 mo ago | 13 | — | Cart FunctionalitySquarespace CommerceSquarespace+16 | 55 patents Peptoid-based antimicrobials and anti‑biofilm coatings for medical and wound applications | — |
| 34 | Cellvie Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney… | $10M | 9 mo ago | 12 | Alexander Schueller Founder & CEO | BootstrapNginxjQuery+2 | 10 patents Optimizing adoptive cell therapy by generating enhanced immune cell populations for immunotherapy | — |
| 35 | ImmunoMet Therapeutics Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies | $10M | 4 mo ago | 9 | Dean Welsch CEO | — | — | — |
| 36 | PranaX Provider of regenerative science to treat various health conditions | $10M | 4 mo ago | — | Steven Greco Founder & COO | WebflowGSAPLenis+16 | — | — |
| 37 | Curative Provider of self collecting COVID-19 testing centers listing platform 48Tech top 20%Innovation top 31%Patents top 33%News top 39% All 11 signals ▾Techtop 20% Innovationtop 31% Patentstop 33% Newstop 39% Fundingtop 42% Growthtop 42% Producttop 49% Moatbottom 44% Marketbottom 43% Globalbottom 33% Fin. healthbottom 14% Tech: 40 technologies across 6/8 capability areas · Cloud: Amazon Web Services, Cloudflare Innovation: 10 patents (top 47% of patent-holders) · 8 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 7 mo ago | 2,251 | — | ContentfulApple iCloud MailGoogle Workspace+31 | 10 patents Molecular diagnostics: nucleic acid purification, sample collection kits, and infection/immunity testing devices. | 1 award |
| 38 | VISIE Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery 42Talent top 28%Innovation top 30%Patents top 32%Funding top 36% All 8 signals ▾Talenttop 28% Innovationtop 30% Patentstop 32% Fundingtop 36% Moattop 38% Techbottom 44% Globalbottom 36% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Innovation: 17 patents (top 49% of patent-holders) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $10M | 13 mo ago | — | Aaron Bernstein Co-Founder & CTO | WordPressPleskMySQL+20 | 17 patents Patents concentrated in computing, sensing & instrumentation | — |
| 39 | Moleculin Biotech Small molecule drugs for leukemia and other cancers | $10M | 3 mo ago | 19 19 → 22 (+16%) · sector median +24% | — | WordPressMySQLPHP+22 | 37 patents Liposomal formulation and lyophilized delivery of annamycin anticancer agent. | — |
| 40 | Biomedical Development Corporation Innovating medical technologies, from development to commercialization, improving clinical outcomes | $10M | 9 mo ago | 9 | — | — | — | — |
| 41 | Bioaffinity technologies Developer of IVD and targets cancer cells for therapeutics | $9M | 10 mo ago | 14 | — | WordPressMySQLPHP+24 | 13 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 42 | Surf Developer of non-invasive ultrasound neuromodulation platform for chronic inflammatory disorders | $6M | 2 mo ago | — | Nishant Doctor Co-Founder & CEO | Framer SitesReactLenis+8 | 14 patents Specialized three-toed and water footwear design and manufacturing | — |
| 43 | MedScout Provider of sales enablement platform to life sciences companies 22Funding top 34%Moat top 48%Talent bottom 49%Product bottom 48% All 8 signals ▾Fundingtop 34% Moattop 48% Talentbottom 49% Productbottom 48% Techbottom 46% Globalbottom 32% Marketbottom 29% Newsbottom 18% Funding: Raised $5.8M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 22/100 | $6M | 3 mo ago | 17 | Skylar Talley Co-Founder & CEO | WebflowSegmentHubSpot+15 | — | 1 partnership |
| 44 | Bayou Surgical Developer of a medical device to improve visualization during surgical procedures | $5M | 7 mo ago | — | Mahmood Khan Co-Founder | — | 25 patents Patents concentrated in health & consumer products | — |
| 45 | Nurocor Developer of a clinical platform designed to accelerate clinical development 40Innovation top 29%Patents top 31%Moat top 32%Funding top 36% All 9 signals ▾Innovationtop 29% Patentstop 31% Moattop 32% Fundingtop 36% Producttop 36% Talentbottom 49% Marketbottom 36% Techbottom 35% Globalbottom 31% Innovation: 24 patents (top 39% of patent-holders) · 24 filings since 2022 vs 0 in 2017-21 Patents: 24 patents matched (strict assignee match) · 24 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $5M | 11 mo ago | 43 | Alex Lazar Founder & President | WordPressApple iCloud MailMySQL+16 | 24 patents Clinical trial software platforms: UI, code generation, and specimen management tools. | — |
| 46 | Modicus Prime Provider of an AI-based decision-making tool for healthcare professionals 22Funding top 41%AI top 45%Talent bottom 49%Global bottom 36% All 5 signals ▾Fundingtop 41% AItop 45% Talentbottom 49% Globalbottom 36% Marketbottom 21% Funding: Raised $3.5M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 22/100 | $4M | 1 mo ago | 8 | Taylor Chartier Founder & CEO | — | — | — |
| 47 | Surgical Automations Developer of surgical robots for surgical procedures 10AI top 45%Funding bottom 47%Global bottom 36%Market bottom 17% All 4 signals ▾AItop 45% Fundingbottom 47% Globalbottom 36% Marketbottom 17% AI: Product described with: ai-based Funding: Raised $3.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 7 mo ago | 3 | — | — | — | — |
| 48 | Ensysce Provider of drug delivery problems with Single-Walled Carbon Nanotubes | $2M | 7 mo ago | 5 | Steven Shafer Co-Founder | WordPress Block EditorWordPressMySQL+21 | — | — |
| 49 | NemaLife Developer of C.elegans based assays for drug discovery | $2M | 6 mo ago | 29 | — | — | 3 patents Microfluidic in vivo bioassay platforms for rapid functional ingredient screening (gut and cognitive health) | 1 job opening · 1 launch |
| 50 | Optimvia Developer of enzymes and a cofactor for therapeutic use | $598K | 2 mo ago | — | Keith Kleeman CEO | — | 44 patents Engineered sulfotransferase biocatalysts for tailored heparan sulfate production | — |
Top 12 Life Sciences companies in Texas
#1
Verily 🦄Series D · Dallas, Texas · founded 2015 · 1564 employees$2.5Braised▾
Verily 🦄
Series D · Dallas, Texas · founded 2015 · 1564 employees
A data platform and technology company purpose-built to power AI-enabled precision health. The company combine deep clinical, regulatory, and technological expertise to provide customers with patient-centric solutions that make healthcare more personal and precise. The solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health.
Fliar Intelligence Index™ 84how this company ranks against its industry peers
News
top 13%Funding
top 14%Talent
top 22%Growth
top 25%Moat
top 26%Tech
top 30%News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Series D (Mar 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 181k LinkedIn followers — 47.2% of this cohort's audience
Funding rounds
- Mar 2026Series D$300M
- Apr 2025Grant (prize money)$14.7M
- Sep 2022PE—
- Dec 2020PE$700M
Founders & team
Investors
Silver Lake, Ontario Teachers' Pension Plan, Temasek, Swiss Re, The Michael J. Fox Foundation, Series X Capital
Tech stack
Apple Icloud MailCore-JsDocusignEmotionGoogle AnalyticsGoogle Cloud
#2
Public · The Woodlands, Texas · founded 1995 · 135 employees$381.3Mraised▾
Public · The Woodlands, Texas · founded 1995 · 135 employees
Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Fliar Intelligence Index™ 76how this company ranks against its industry peers
Funding
top 20%Patents
top 24%Talent
top 28%Growth
top 30%Tech
top 35%Innovation
top 40%Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) · Last round Post IPO (Feb 2026)
Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 · Latest publication 2026
Talent: Analyst team rating 5/5 · 2 named leaders on record
Audience (LinkedIn): 24k LinkedIn followers — 6.4% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$55.7M
- Aug 2022Post IPO$42.9M
- Mar 2017Post IPO$10.5M
- Dec 2014Post IPO$4.7M
Founders & team
Investors
Bay City Capital, New Enterprise Associates, Military Health, BCM Technologies, Genechem
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApple Icloud MailCore-JsDocusign
#3
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Series A · Dallas, Texas · founded 2018 · 8 employees
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
Founders & team
Investors
Maryland Momentum Fund, Parent Project Muscular Dystrophy, RA Capital Management, USM
Tech stack
CloudflareCloudflare Bot ManagementDiviGodaddyGodaddy CoblocksGoogle Analytics
#4
Public · Irving, Texas · founded 1996 · 1339 employees$1.1Braised▾
Public · Irving, Texas · founded 1996 · 1339 employees
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Moat
top 15%Funding
top 17%Product
top 19%Market
top 28%Innovation
top 38%Growth
top 40%Moat: Editorial + unicorn rating 9/10 · Unicorn
Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series D (Apr 2025)
Product: 3 distinct product lines · Company stage: Public
Funding rounds
- Apr 2025Series D$168M
- Jan 2023Conventional Debt—
- May 2021Series D$830M
- Oct 2020Conventional Debt$75M
Investors
Coatue, Highland Capital Management, Orbimed, T. Rowe Price, Millennium Management, Neuberger Berman
Tech stack
BootstrapCart FunctionalityCloudflareCloudflare Bot ManagementCookieyesElementor
#5
Public · Houston, Texas · founded 2017 · 5 employees$22.5Mraised▾
Public · Houston, Texas · founded 2017 · 5 employees
Developer of treatments for primary and metastatic cancers in the brain and central nervous system. It offers a pipeline of anti-cancer drug candidates including berubicin that appears to cross the blood brain barrier and kill tumor cells and TPI 287 for glioblastoma multiforme.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 23%News
top 23%Growth
top 25%Talent
top 43%Tech
bottom 45%Global
bottom 43%Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: AD/Director, Business Development
Funding rounds
- May 2026Series B$22.5M
Founders & team
Investors
Falcon Capital
Tech stack
AccessibeCloudflareCloudflare Browser InsightsCookieyesDiviFlywheel
#6
Public · Austin, Texas · founded 2016 · 89 employees$165.4Mraised▾
Public · Austin, Texas · founded 2016 · 89 employees
Shattuck Labs is a developer of an immunotherapy platform for oncology and other diseases. The company has developed ARC (Agonist Redirected Checkpoints), which hinges on the development of bispecific biologics that simultaneously block candidate checkpoint molecules in cancer while also stimulating TNF superfamily costimulatory receptors on T cells and innate cells. The company claims that ARC is adaptable to most of the checkpoint targets currently in clinical development.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Funding rounds
- Aug 2025Post IPO$103M
- Jun 2020Series C$83M
- Feb 2020Series B$25.4M
- May 2018Series B$46.6M
Investors
Hunter Trust, Redmile Group, Janus Henderson Investors, Fidelity Investments, EcoR1, Hatteras Venture Partners
#7
Public · Houston, Texas · founded 1991 · 67 employees$153.9Mraised▾
Public · Houston, Texas · founded 1991 · 67 employees
Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Talent
top 15%Funding
top 18%News
top 47%Tech
top 50%Moat
top 50%Market
bottom 43%Talent: Analyst team rating 5/5
Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) · Last round Grant (prize money) (Aug 2025)
News: 3 BI events in 12 mo (of 22 tracked, 6 types) · +0% YoY · Top themes: Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Aug 2025Grant (prize money)$1.3M
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
Investors
New Enterprise Associates, Aisling Capital, state.tx.us, FDA, NIH, Blue Owl
Tech stack
Apache Http ServerApple Icloud MailBootstrapCookieyesGodaddyGoogle Analytics
#8
Series C · Houston, Texas · founded 2017 · 10 employees$30Mraised▾
Series C · Houston, Texas · founded 2017 · 10 employees
Developer of endovascular robotics and steerable guidewires. The company is developing robotic systems that can enable expert navigation of the body's complex vascular network to treat life-threatening conditions like cerebrovascular disorders.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Innovation
top 23%Patents
top 26%Funding
top 28%Moat
top 28%Talent
bottom 49%Global
bottom 40%Innovation: 128 patents (top 15% of patent-holders) · 72 filings since 2022 vs 56 in 2017-21 · Deep-tech classification: Tech Hardware
Patents: 128 patents matched (strict assignee match) · 72 filings since 2022 vs 56 in 2017-21 · Latest publication 2026
Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series C$30M
Founders & team
Investors
Crescent Enterprises
#9
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Public · Austin, Texas · founded 1993 · 85 employees
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 29%Tech
top 46%Market
bottom 46%Fin. health
bottom 36%Growth
bottom 35%Global
bottom 30%Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) · Last round Post IPO (Sep 2025)
Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Hsts
Market: 85 employees (top 40% of Genomics) · Revenue ~$9.2M · Top-10,000,000 web property
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Chelton Clinic) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
Tech stack
Apple Icloud MailBeaver BuilderCloudflareCore-JsDocusignFacebook Login
#10
Series D · Houston, Texas · founded 2017 · 21 employees$201.7Mraised▾
Series D · Houston, Texas · founded 2017 · 21 employees
Developer of a robotic system for endoluminal and single-incision surgery. The system aims to enable and enhance physician capabilities during surgical procedures. It focuses on eliminating or minimizing external incisions to reduce patient trauma. The goal is to improve patient outcomes, accelerate recovery, and reduce healthcare costs. The system is under development and not for commercial sale.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Innovation
top 15%Patents
top 22%Funding
top 26%Moat
top 41%Talent
bottom 49%Tech
bottom 43%Innovation: 135 patents (top 15% of patent-holders) · 131 filings since 2022 vs 4 in 2017-21 · Deep-tech classification: Tech Hardware
Patents: 135 patents matched (strict assignee match) · 131 filings since 2022 vs 4 in 2017-21 · Latest publication 2026
Funding: Raised $202M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series D (May 2025)
Audience (LinkedIn): 14k LinkedIn followers — 3.7% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. NVIDIA) announced in 12 mo
Funding rounds
- May 2025Series D$30.7M
- Dec 2023Series C$42M
- Jun 2021Series C$76.1M
- Apr 2021Series B$69M
Founders & team
Investors
Crescent Enterprises, McNair, Puma Venture Capital, UTHealth
#11
Series B · Fort Worth, Texas · founded 2016 · 7 employees$30.9Mraised▾
Series B · Fort Worth, Texas · founded 2016 · 7 employees
Nacuity Pharmaceuticals is developing therapies for treating retinitis pigmentosa and other ophthalmological disorders. The company's lead candidate NPI-001 is used for treating retinitis pigmentosa, NPI-002 for prevention or treatment of cataract, and NPI-001 Ophthalmic Insert for the treatment of ocular effects of Cystinosis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Dec 2025Series B$8.4M
- Jun 2022Series B$16.5M
- Mar 2021Series A$3.2M
- Jul 2017Series A$9.2M
Founders & team
Investors
Foundation Fighting Blindness, Tarnagulla Ventures, RD Fund
Tech stack
Apache Http ServerExactmetricsGodaddyGoogle AnalyticsGoogle Font ApiGsap
#12
Public · Houston, Texas · founded 2006 · 19 employees$9.7Mraised▾
Public · Houston, Texas · founded 2006 · 19 employees
Moleculin Biotech is preclinical and clinical-stage company focused on the development of anti-cancer drug candidates and was founded based on the discoveries made at M.D. Anderson Cancer Center. Its lead product candidate Annamycin, an anthracycline molecule will be entering phase IIb trials for the treatment of relapsed or refractory acute myeloid leukemia. Its small molecules pipeline also has WP1066 portfolio 3 candidates which are focused on the modulation of tumor cell signaling mechanisms WP1122 that targets the metabolism of tumors. These candidates are in the IND-filing phase for Cutaneous T-cell lymphoma, Glioblastoma, and Pancreatic cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Funding rounds
- Feb 2026Post IPO$8.3M
- Feb 2018Post IPO$9M
- Dec 2017Grant (prize money)$2M
- Oct 2014Conventional Debt$1.4M
Investors
UT System, Falcon Capital, SRG
Tech stack
AccessibeCloudflareCloudflare Bot ManagementCookieyesDiviFlywheel
Funding & investor landscape
$13Btotal disclosed funding
408companies funded
1,566disclosed rounds
5rounds last 90 days
Most active investors
Notable founders
Andrew Conrad
Co-Founder · Verily
Jessica Mega
Co-Founder · Verily
Ivan Cheung
Board of Directors · Lexicon Pharmaceuticals
Ray Debbane
Chairman of Board · Lexicon Pharmaceuticals
Sudhish Sharma
Co-Founder · Secretome Therapeutics
Muthukumar Gunasekaran
Co-Founder · Secretome Therapeutics
John Climaco
CEO · CNS Pharmaceuticals
Eduardo Fonseca
CEO · XCath
Kurt Azarbarzin
CEO · EndoQuest Robotics
Halden Conner
CEO & President · Nacuity Pharmaceuticals
Kyle Ryder
Founder · VeraDermics
Ross Johnson
Co-Founder · Pattern Bioscience
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN TEXAS · Health & Bio
How research on Biotechnology in Texas is moving
A read on the academic research around Biotechnology in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 297 papers.
Texas A&M and UT Southwestern lead Texas's moderately optimistic biotechnology research, dominated by CRISPR and bacterial genetics with strong recent momentum toward therapeutic breakthroughs.
297 papers · stance +0.53 · 41% breakthrough · 15% concern
top institutions
- Texas A&M University75
- The University of Texas Southwestern Medical Center41
- The University of Texas MD Anderson Cancer Center39
- Texas Tech University38
- The University of Texas at Austin31
leading researchers
Amit Dhingra · June Labbancz · Min Ji Jang · Muhammad Haroon · Reza Ovissipour · Abdullah bin Talat
prism intelligence · tone & topics
94% positive · 3% critical tone
Medical ResearchHealthPharmaceuticalsAgricultureBiologyGenetics
▲
Breakthroughs111 · 37%
▼ 47%→35% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene research surged from 1 to 11 papers, driving Breakthroughs despite field-share falling from 47% to 35%.
rising sub-themes (early→recent)
- Gene1→11
- Gene expression1→4
- Mutation1→4
- Cell1→3
- Messenger RNA2→3
Newly emergingTranscription (linguistics) 0→6 · Function (biology) 0→6 · Recombinant DNA 0→4
Landmark Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway · 4,674 cites
◆
Advancements119 · 40%
▲ 29%→43% share
▲1.5× share momentum0 median citations82% since 2021mostly empirical
Advancements field-share intensifying from 29% to 43%, led by newly emerging Immune system, Sorghum, and Gene topics.
rising sub-themes (early→recent)
- Phenotype1→3
- Selection (genetic algorithm)1→3
Newly emergingImmune system 0→6 · Sorghum 0→6 · Gene 0→6
Landmark A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity · 1,667 cites
▼
Concerns40 · 13%
▼ 17%→12% share
▼0.7× share momentum0 median citations72% since 2021mostly reviews
Concerns field-share cooling from 17% to 12%, though Disease newly re-emerged with 3 papers alongside rising Abiotic stress.
rising sub-themes (early→recent)
- Disease3
- Abiotic stress2
- T cell2
- Sustainability2
- Livestock2
Newly emergingDisease 0→3
Landmark Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden · 1,025 cites
Common questions
How many Life Sciences companies are there in Texas, United States?
Radar tracks 904 indexable Life Sciences companies headquartered in Texas, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Texas, United States?
The Life Sciences companies in Texas, United States on this list have raised a combined $13B in disclosed equity funding across 408 funded companies.
Which is the highest-funded Life Sciences company in Texas, United States?
Verily is the highest-funded Life Sciences company in Texas, United States, with $2.5B in disclosed equity funding.
How many Life Sciences companies in Texas, United States are funded?
408 of the 904 Life Sciences companies in Texas, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Texas, United States?
3 Life Sciences companies in Texas, United States on this list are valued at $1B or more.
Who are the top investors in Texas, United States Life Sciences companies?
The most active investors in Texas, United States Life Sciences companies on this list include HHS, JLABS, National Science Foundation, Green Park & Golf Ventures, MassChallenge.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.